Atossa Genetics (NASDAQ:ATOS) Price Target Raised to $7.75

Key Points

• Ascendiant Capital Markets has increased its price target for Atossa Genetics (NASDAQ:ATOS) from $7.50 to $7.75, maintaining a "buy" rating for the stock.
• The current average target price for Atossa Genetics is $6.25, with one analyst giving it a "strong buy" and two others rating it as a "buy".
• Despite a recent drop of 3.5% in share price, Atossa Genetics reported a quarterly EPS of (-$0.07), slightly missing analysts' expectations.

Atossa Genetics (NASDAQ:ATOS - Free Report) had its price objective increased by Ascendiant Capital Markets from $7.50 to $7.75 in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Craig Hallum raised Atossa Genetics to a "strong-buy" rating and set a $4.00 target price for the company in a research note on Thursday, June 5th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $6.25.

Atossa Genetics Price Performance

Shares of ATOS stock traded down $0.02 during trading hours on Monday, reaching $0.83. 467,197 shares of the company's stock were exchanged, compared to its average volume of 496,433. The company has a market cap of $107.33 million, a P/E ratio of -3.61 and a beta of 1.10. The company's 50 day moving average is $0.81 and its two-hundred day moving average is $0.79. Atossa Genetics has a 1 year low of $0.55 and a 1 year high of $1.66.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). As a group, analysts predict that Atossa Genetics will post -0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Atossa Genetics

Hedge funds have recently bought and sold shares of the company. Hudson Bay Capital Management LP purchased a new position in Atossa Genetics during the second quarter worth $26,000. Millennium Management LLC acquired a new stake in shares of Atossa Genetics during the fourth quarter worth $28,000. Two Sigma Advisers LP boosted its holdings in shares of Atossa Genetics by 214.1% during the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock worth $40,000 after purchasing an additional 28,900 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Atossa Genetics during the second quarter worth $49,000. Finally, Bank of America Corp DE boosted its holdings in shares of Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company's stock worth $83,000 after purchasing an additional 35,629 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Genetics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.